Buzz & LABS: 2 Canadian Pot Stocks To Explore

  • March 03, 2021 08:54 AM EST
  • Shreya Biswas
    Shreya Biswas
    Multimedia Journalist Shreya Biswas
    138 Posts

    Shreya Biswas is a multimedia journalist with a degree from the Asian College of Journalism. Previously a literature student-turned-political reporter, she now writes on market trends at Kalkine Media. When not chasing deadlines, she enjoys blogging....

Buzz & LABS: 2 Canadian Pot Stocks To Explore

Source: Lumppini, Shutterstock

Summary

  • Pharmadrug stock hit its highest point in nearly two years on February 17, at C$ 0.195.
  • It records a year-to-date (YTD) growth of nearly 65 per cent.
  • Canadian company MediPharm Labs recently conducted a bought deal offering to raise gross proceeds of about C$ 20 million.
  • MediPharm stocks post a YTD price growth of about 12 per cent.

 

While battling the ups and downs of the coronavirus pandemic last year, one in four adult Canadians reportedly used cannabis at least once. Yes, that’s what a 2020 Commonwealth Fund study, released last week, found! On that ‘high’ note, let’s check out two discounted pot stocks from Canada: Pharmadrug Inc (BUZZ:CNX) and MediPharm Labs Corp (TSX:LABS).

The Commonwealth Fund survey, which compared Canada's health systems to those of 10 other nations, found that 23 per cent of the Canadian population used cannabis in 2020. In comparison, its international peers reported just nine per cent.

But it is not just the usage in the home country that Canadian pot producers are looking at. With the promise of cannabis legalization south of the border still dangling before it, the Canadian pot business is seeking expansion in the US market.

Let’s take a look at Pharmadrug and MediPharm’s recent stock performances.

 

Pharmadrug Inc (BUZZ:CNX)


Biotech company Pharmadrug focuses its business on medical cannabis and psychedelics. While it is based in Toronto, Pharmadrug has major operations in Germany. Earlier in February, it acquired peer Sairiyo Therapeutics to expand its business model.

Pharmadrug stock hit its highest point in nearly two years on February 17, at C$ 0.195. Although the share has since descended, it still records a year-to-date (YTD) growth of nearly 65 per cent.

The Toronto-based company saw an average of nearly eight million stocks trade hands in the last one month. It currently has a market cap* of about C$ 45.6 million.

©Kalkine Group 2021

 

MediPharm Labs Corp (TSX:LABS)


Canadian company MediPharm Labs delves in the extraction, distillation and production of derivative pot products, such as cannabis oil. It recently conducted a bought deal offering of 34.5 million units at a price of C$ 0.58 apiece to raise gross proceeds of about C$ 20 million.

MediPharm stocks post a YTD price growth of about 12 per cent, with an average share movement volume of nearly three million for the past 10 days. With a market cap* of about C$ 101 million, the Barrie-based company posts a price-to-book ratio of 0.724 and a debt-to-equity ratio of 0.3.

Earlier in February, MediPharm was awarded the cannabis drug license (CDL) by Health Canada.

 

*as per TMX

 


Disclaimer
The website https://kalkinemedia.com/ca is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001. The principal purpose of the content on the website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK